Analysts Set Expectations for IceCure Medical Q1 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM – Free Report) – Equities research analysts at Brookline Capital Markets issued their Q1 2027 earnings estimates for shares of IceCure Medical in a research note issued on Wednesday, November 18th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings per share of ($0.75) for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($4.61) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.62) EPS and FY2029 earnings at $0.30 EPS.

A number of other research firms have also weighed in on ICCM. Zacks Research upgraded shares of IceCure Medical from a “strong sell” rating to a “hold” rating in a report on Monday, October 12th. Wall Street Zen cut IceCure Medical from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IceCure Medical presently has an average rating of “Hold” and a consensus target price of $30.00.

Read Our Latest Report on IceCure Medical

IceCure Medical Stock Performance

ICCM stock opened at $1.00 on Friday. The firm’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $6.74. IceCure Medical has a 12-month low of $0.65 and a 12-month high of $22.20.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd. is an Israel-based medical technology company that develops and commercializes minimally invasive cryoablation systems. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, offering a percutaneous approach to treating tumors. The company’s ProSense system is designed for image-guided cryoablation and is used in procedures involving breast, kidney, lung, bone and other tumors. IceCure also offers the IceSense3 system for treating benign breast fibroadenomas.

Featured Articles

Earnings History and Estimates for IceCure Medical (NASDAQ:ICCM)

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.